进入7月以后，第三方数据显示，公司两大品牌线上销售有所回暖。 Sandalwood电商数据监测显示，巨子生物旗下的可复美品牌从第二季度的事件冲击中恢复过来，1- 7月合计GMV同比增长32%，7月GMV同比增长62%，同属巨子的可丽金，1-7月GMV同比下跌7%，7月 GMV同比增长35%。 智通财经记者注意到，在经历过去几年业绩狂飙后，今年上半年，重组胶原蛋白赛道开始释放降温 信号，在巨子生物之前，锦波生物（832982.BJ）交出的半年报也显示公司Q2业绩增速大幅放缓，加剧 市场对重组胶原蛋白行业的担忧。与此同时，更多厂商还在加速涌入，上半年敷尔佳（301371.SZ）、 福瑞达（600223.SH）等化妆品厂商均有相关技术或产品推出。 （智通财经记者 罗祎辰） （责任编辑：田云绯） 智通财经8月27日讯（记者 罗祎辰）今年"618大促"期间爆发的质量风波显著冲击了巨子生物 （02367.HK）业绩，公司今日晚间发布的财报显示，上半年营收和归母净利润同比仍然维持增长，但 增速较上年同期已明显放缓。进入7月后，有第三方数据显示，公司线上销售有所回暖。 今日晚间，巨子生物发布半年报，上半年实现营收31.13亿 ...

Core Viewpoint - The company, Juzhi Biotechnology, reported a revenue of 3.113 billion yuan for the first half of the year, reflecting a year-on-year growth of 22.5%, while net profit attributable to shareholders reached 1.182 billion yuan, up 20.2% year-on-year. However, the growth rate has slowed compared to the previous year's high growth rates of 58.2% and 47.4% respectively, indicating a downward shift in growth momentum [1][3]. Group 1: Financial Performance - The company's revenue growth is primarily driven by its two main brands, Kefu Mei and Keli Jin, which contributed 97.8% of total revenue. Kefu Mei generated 2.542 billion yuan in revenue, a 22.7% increase, while Keli Jin achieved 503 million yuan, growing by 26.9% [3][5]. - The gross profit margin for the first half of the year was 81.7%, slightly down from 82.4% in the previous year, but still significantly higher than competitors like Proya [5][6]. - Sales expenses reached 1.059 billion yuan, a year-on-year increase of 18.7%, accounting for 34.0% of revenue, indicating aggressive marketing strategies to maintain market position [7]. Group 2: Market Dynamics - The company faces challenges from a slowing collagen market and a trust crisis affecting brand reputation, leading to a decline in consumer confidence [1][4]. - The company reported a significant increase in trade receivables, which surged to 466 million yuan, a 230% increase from the end of 2024, raising concerns about potential inventory buildup and cash flow efficiency [8]. - The company is focusing on online direct sales, which generated 1.816 billion yuan, accounting for 58.4% of total revenue, highlighting the importance of digital channels in its growth strategy [6]. Group 3: Industry Positioning - Juzhi Biotechnology has transitioned from being a market participant to a rule-maker by participating in the drafting of the national industry standard for recombinant collagen dressings, which raises questions about fairness and potential conflicts of interest in standard-setting [9]. - The company’s involvement in standard-setting is seen as a recognition of its technical capabilities, but it also poses risks of creating barriers to competition and tailoring regulations to benefit itself [9].

Core Viewpoint - The financial performance of the company shows a significant slowdown in growth compared to the previous year, raising concerns about its future prospects [1] Financial Performance - The company reported a revenue of 31.13 billion and a net profit of 11.82 billion for the first half of the year [1] - Revenue growth has decreased to 22.5% and net profit growth to 20.2%, compared to last year's growth rates of 58% and 47% respectively [1] Controversy and Market Impact - Since May, the company has faced scrutiny over the "recombinant collagen content" issue, which led to a market value loss exceeding 300 billion [1] - The company acknowledged the limitations of its testing methods in response to the controversy [1] Industry Positioning - Following the controversy, the company has positioned itself as a "rule-maker" in the industry by participating in the drafting of the new pharmaceutical industry standard for "recombinant collagen dressings" [1] - This raises questions about the potential conflict of interest when a participant in the industry also sets the rules [1]

Group 1 - The core viewpoint of the news is that 巨子生物 (Giant Bio) reported a revenue increase of 22.5% year-on-year for the first half of 2025, despite a nearly 5% drop in stock price [1] - The company's total revenue reached approximately 31.13 billion yuan, with a gross profit of about 25.42 billion yuan, reflecting a growth of 21.5% [1] - Net profit attributable to shareholders was around 11.82 billion yuan, marking a 20.2% increase compared to the previous year [1] Group 2 - The 可复美 brand generated revenue of 25.4 billion yuan, up 22.7% year-on-year, while the 可丽金 brand achieved revenue of 5 billion yuan, growing by 26.9% [1] - In the same period last year, the company's revenue and net profit attributable to shareholders had much higher growth rates of 58.2% and 47.4%, respectively [1] - The 可复美 brand's revenue growth was 68.6% last year, and 可丽金's was 23.6% [1] Group 3 - 财通证券 (Caitong Securities) noted that the 可复美 brand faced some impact from a public relations incident, but the overall situation remains manageable [2] - During the 618 shopping festival, 可复美 ranked 16th on Tmall, down from 12th in 2024, indicating a slight decline in online performance [2] - Despite the challenges, offline sales channels such as pharmacies, hospitals, and Sephora remain stable, with positive user feedback on core products [2] Group 4 - After the public relations incident, sales data showed a rebound, with July figures indicating a 70% year-on-year growth in GMV on Tmall and a 17% increase on Douyin [2] - The company expects a gradual recovery in sales for the second half of the year as collaborations with key influencers increase [2]

财通证券此前指出，可复美5.24舆情事件后受到一定影响但整体可控，根据天猫大美妆618期间可复美 天猫排名排名16（24年第12名）。线下方面，公司药店、医院、丝芙兰等渠道稳定覆盖，核心械二产品 用户口碑较好，预计线下销售受影响较小。线上方面，舆情发酵期间达播停播影响大促后半段销售，7 月以来部分头部主播已恢复直播可复美产品，合作频次逐加大，经营数据出现反弹势头，久谦数据显示 7月可复美天猫和抖音GMV分别同比增长70%、17%，下半年销售逐步回升可期。 智通财经APP获悉，巨子生物(02367)跌近5%，截至发稿，跌4.92%，报52.15港元，成交额4.53亿港元。 消息面上，巨子生物公布2025年中期业绩，收入约31.13亿元，同比增长22.5%；毛利约25.42亿元，同 比增长21.5%；归属于母公司持有者盈利约11.82亿元，同比增长20.2%。报告期内，可复美品牌实现收 入25.4亿元，同比增长22.7%；可丽金品牌实现收入5亿元，同比增长26.9%。值得注意的是，去年同 期，该公司营收和归母净利润的同比增幅分别为58.2%和47.4%。其中可复美品牌收入同比增幅68.6%， 可丽金品牌收入同比增 ...

Summary of Giant Biogene Holding (2367.HK) Earnings Call Company Overview - **Company**: Giant Biogene Holding (2367.HK) - **Market Cap**: HK$58.7 billion / $7.5 billion - **Industry**: China/Korea Cosmetics & Jewelry Key Financial Highlights - **1H25 Performance**: - Sales increased by 23% year-over-year (yoy) to Rmb3,113 million, in line with Goldman Sachs estimates (GSe) [17] - Net income (NI) rose by 20% yoy to Rmb1,182 million, matching GSe [22] - Operating profit grew by 25% yoy to Rmb1,360 million, exceeding GSe by 6% [21] Core Insights - **Sales Growth**: - Professional skin treatment products sales grew by 23% yoy, with Comfy brand sales up 23% to Rmb2,542 million, and Collgene sales up 27% to Rmb503 million [17] - Cosmetics sales increased by 24% yoy to Rmb2,410 million, while medical device sales rose by 17% to Rmb693 million [17] - **Channel Performance**: - Direct sales increased by 26% yoy to Rmb2,325 million, with online direct-to-consumer (DTC) sales growing by 134% [17] - Distribution sales grew by 12% yoy to Rmb787 million [18] Margin Analysis - **Gross Margin**: Contracted by 0.7 percentage points yoy to 81.7%, in line with GSe [19] - **Operating Margin**: Expanded by 0.9 percentage points yoy to 43.7%, exceeding GSe by 2.4 percentage points due to lower selling and R&D expenses [21] - **Net Margin**: Declined by 1.8 percentage points yoy to 38.7%, consistent with GSe [22] Guidance and Future Outlook - **Full Year Guidance**: - Sales growth expected at 25-28% and NI growth at 21-24% yoy [1] - Management plans to invest in brand revitalization in 2H25, anticipating a stronger KOL lineup ahead of Double 11 [2] - **Earnings Revisions**: - 2025E NI revised to Rmb2.4 billion, reflecting a 16% yoy increase, with sales growth of 25% [23] Valuation and Price Target - **Target Price**: Remains unchanged at HKD71, implying a 29% upside from the current price of HKD54.85 [1][24] - **P/E Ratio**: Target 2025-26E P/E set at 25x, based on expected NI growth of 16% and 27% for 2025E and 2026E respectively [24] Risks - **Key Risks**: - Slower-than-expected growth in the professional skin treatment market - Increased competition - Regulatory risks [24][27] Additional Insights - **Operational Efficiency**: Improved ROI measured by GPM-Selling expenses ratio, which increased by 0.4 percentage points yoy [1] - **Cost Management**: Selling and distribution expenses increased by 19% yoy but were lower than GSe, contributing to improved margins [19][20] This summary encapsulates the key points from the earnings call, highlighting the company's performance, future outlook, and associated risks.

Performance Summary - China People's Insurance Group reported revenue of 324.12 billion yuan, a year-on-year increase of 10.87%, and a net profit of 26.67 billion yuan, up 13.98% [1] - China Life Insurance recorded revenue of 239.49 billion yuan, a 2.2% increase, with a net profit of 40.93 billion yuan, growing by 6.9% [1] - CNOOC's revenue was approximately 207.61 billion yuan, down 8.45%, with net profit around 69.5 billion yuan, a decrease of 13% [2] - Meituan's revenue reached 178.40 billion yuan, up 14.7%, but adjusted net profit fell by 41% to 12.44 billion yuan [3] - CITIC Bank's revenue was 105.43 billion yuan, down 2.96%, while net profit increased by 2.8% to 36.48 billion yuan [3] - Fosun International's revenue decreased by 10.8% to 87.28 billion yuan, with net profit down 8.2% to 0.66 billion yuan [3] - New Hope Energy reported revenue of 55.67 billion yuan, a 2% increase, but net profit decreased by 5.6% to 2.43 billion yuan [4] - China Cinda's revenue was 34.36 billion yuan, down 2%, while net profit increased by 5.8% to 2.28 billion yuan [5] - China Orient Group's revenue decreased by 12% to 19.86 billion yuan, but net profit surged by 116% to 0.20 billion yuan [6] - Shimao Group's revenue fell by 49% to 14.80 billion yuan, with a net loss of 8.93 billion yuan, narrowing by 61% [7] - Chongqing Steel's revenue was approximately 13.08 billion yuan, down 13.26%, with a net loss of 0.13 billion yuan, narrowing by 81% [8] - United Group's revenue increased by 197.3% to 12.08 billion yuan, with a net profit of 1.69 billion yuan, reversing from a loss of 0.21 billion yuan [9] - Chow Sang Sang's revenue decreased by 2.5% to 11.04 billion yuan, while net profit increased by 71.4% to 0.90 billion yuan [10] - Tianhong International's revenue was 11.03 billion yuan, down 1.86%, with net profit rising by 53.33% to 0.42 billion yuan [11] - Meidong Automotive's revenue fell by 4.9% to 10.14 billion yuan, with a net loss of approximately 0.82 billion yuan, expanding by about 29 times [12] - Jian Sha Tsui's revenue was 8.24 billion yuan, down 6.6%, with net profit of 2.33 billion yuan, a decrease of 7.06% [13] - Sino Land's revenue decreased by 6.64% to 8.18 billion yuan, with net profit down 8.7% to 4.02 billion yuan [14] - Xinyi International's revenue was 8.10 billion yuan, down 5.7%, with net profit of 0.14 billion yuan, a decrease of 19.22% [15] - Fuyao Glass reported revenue of approximately 7.74 billion yuan, down 27.7%, with net profit of approximately 0.26 billion yuan, a decrease of 82.6% [16] - Tianjin Port Development's revenue increased by 3% to 6.95 billion yuan, while net profit decreased by 17.3% to 0.35 billion yuan [17] - Guotai Junan International's revenue was approximately 2.83 billion yuan, up 30%, with net profit of approximately 0.55 billion yuan, a growth of 182% [21] - IGG's revenue decreased by 0.5% to 2.72 billion yuan, with net profit down 2.85% to 0.32 billion yuan [22] - China Aircraft Leasing's revenue was 2.40 billion yuan, down 4.86%, while net profit increased by 6.66% to 0.14 billion yuan [22] - China Orient Education's revenue increased by 10.2% to 2.19 billion yuan, with net profit rising by 48.4% to 0.40 billion yuan [23] Corporate News - China Shengmu signed a new procurement framework agreement with Yiyingmei Dairy for milk powder [24] - Rongchang Bio's clinical trial for Taitasip in treating IgA nephropathy reached its primary endpoint in Phase III [24] - China Huaxing's Bagua City project is expected to start construction in October, with completion by the end of 2026 [24] Buyback Activities - Tencent Holdings repurchased 909,000 shares for 550 million HKD at prices between 596-614.5 HKD [24] - HSBC repurchased 1.5472 million shares for approximately 156 million HKD at prices between 100.2-101.5 HKD [24] - Hang Seng Bank repurchased 210,000 shares for approximately 23.49 million HKD at prices between 111.5-112.2 HKD [24] - MGM China repurchased 1 million shares for approximately 16.02 million HKD at prices between 15.92-16.13 HKD [24]

Group 1 - The core viewpoint of the articles highlights the robust performance growth of the companies, with 巨子生物 achieving a revenue of RMB 3.11 billion, a year-on-year increase of 22.5%, and a net profit of RMB 1.18 billion, up 20.6% [1] - The revenue growth for 巨子生物 is attributed to deepening online and offline channels, enhancing operational capabilities, consolidating star products, upgrading core products, and strengthening brand marketing [1] - 可丽金 reported a sales revenue of RMB 502.7 million, a 26.9% increase compared to the same period in 2024, accounting for 16.1% of total revenue, driven by online channel expansion and successful upgrades of star products [2] Group 2 - 巨子生物 invested RMB 41 million in R&D, representing 1.3% of its revenue, with over 140 projects under research and 186 patents authorized or applied for [1] - 可丽金's products are available in approximately 1,700 public hospitals, 3,000 private hospitals and clinics, over 130,000 chain pharmacies, and around 6,000 CS/KA stores, utilizing various online platforms for sales and promotion [2] - Looking ahead to the second half of 2025, 可丽金 plans to strengthen its technological research and brand communication, ensuring sustainable and high-quality operational capabilities [2]

巨子生物(02367)公布2025年中期业绩，收入约31.13亿元，同比增长22.5%;毛利约25.42亿元，同比增长 21.5%;归属于母公司持有者盈利约11.82亿元，同比增长20.2%;每股基本盈利1.14元。 公告称，收入增长的主要原因是报告期内公司深耕线上和线下渠道、提高精细化运营能力，巩固明星单 品的增长以及迭代升级核心产品并加强品牌营销，提升品牌影响力。 ...

GIANT BIOGENE HOLDING CO., LTD 巨子生物控股有限公司 （於 開 曼 群 島 註 冊 成 立 的 獲 豁 免 有 限 公 司） （股 份 代 號：2367） 董事名單及其角色和職能 巨子生物控股有限公司董事會（「董事會」）成 員 載 列 如 下： 執行董事 嚴建亞先生 （董 事 長） 葉娟女士 方娟女士 張慧娟女士 嚴鈺博女士 獨立非執行董事 黃進先生 單文華先生 黃斯穎女士 董 事 會 轄 下 設 有 四 個 委 員 會。下 表 載 列 各 董 事 會 成 員 在 這 些 委 員 會 中 所 擔 任 的 職 務。 | 董事會委員會 | 審 核 | 提 名 | 薪 酬 | 公司管治 | | --- | --- | --- | --- | --- | | 董 事 | 委員會 | 委員會 | 委員會 | 委員會 | | 嚴建亞先生 | | C | M | C | | 葉娟女士 | | | | | | 方娟女士 | | | | M | | 張慧娟女士 | | | | | | 嚴鈺博女士 | | | | | | 黃進先生 | M | M | | | | 單文華先生 | M | | C | ...